Esperion Therapeutics (ESPR) Proxy filing summary

Executive summary

• Annual meeting scheduled for May 28, 2026, with virtual participation available for shareholders.

• Shareholders are encouraged to review proxy materials online or request copies by May 14, 2026.

Voting matters and shareholder proposals

• Election of two Class I directors: J. Martin Carroll and Sheldon L. Koenig.

• Advisory vote on executive compensation (say-on-pay) is on the agenda.

• Ratification of Ernst & Young LLP as independent auditor for fiscal year ending December 31, 2026.

• Proposal to amend the 2022 Stock Option and Incentive Plan.

• Proxies may vote on other business arising at the meeting or any adjournment.

Board of directors and corporate governance

• Board recommends voting in favor of all proposals and director nominees.